CTI BioPharma Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	FY 2014	FY 2013	FY 2012	FY 2011
Period Ending	Dec '14 Dec 31, 2014	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012	Dec '11 Dec 31, 2011
Cash & Equivalents	111.12	570.09	248.51	16.39
Short-Term Investments	-	32	32	32
Cash & Short-Term Investments	111.12	602.09	280.51	48.39
Cash Growth	-81.54%	114.64%	479.69%	-
Accounts Receivable	-	-	103.82	-
Other Receivables	0.01	0.69	1.04	0.42
Receivables	0.01	0.69	104.86	0.42
Inventory	206.36	2,491	3,165	991.99
Prepaid Expenses	41.33	63.49	43.78	333.32
Other Current Assets	0.04	102.96	14.62	5.1
Total Current Assets	358.85	3,261	3,609	1,379
Property, Plant & Equipment	9,315	9,976	10,601	10,151
Other Intangible Assets	16.34	23.5	15.94	11.03
Long-Term Deferred Charges	-	3,072	1,154	327.31
Other Long-Term Assets	10.15	40.45	130.15	102
Total Assets	9,700	16,373	15,510	11,970
Accounts Payable	50.48	324.74	105.89	367.72
Accrued Expenses	17.46	100.9	113.43	25.68
Short-Term Debt	899.5	1,979	712.68	-
Current Portion of Long-Term Debt	2,080	700	400	-
Current Unearned Revenue	-	151.17	199.93	-
Other Current Liabilities	3.31	2.57	102.45	586.25
Total Current Liabilities	3,051	3,259	1,634	979.64
Long-Term Debt	7,759	7,311	6,400	5,000
Other Long-Term Liabilities	0	-0	-	-
Total Liabilities	10,882	10,733	8,164	6,007
Common Stock	5,323	5,323	5,323	4,435
Additional Paid-In Capital	7,188	6,472	5,978	2,871
Retained Earnings	-13,757	-6,163	-3,916	-1,342
Comprehensive Income & Other	62.92	7.02	-39.54	-
Shareholders' Equity	-1,182	5,640	7,346	5,964
Total Liabilities & Equity	9,700	16,373	15,510	11,970
Total Debt	10,739	9,990	7,513	5,000
Net Cash (Debt)	-10,628	-9,388	-7,232	-4,952
Working Capital	-2,692	1.98	1,975	399.59
Tangible Book Value	-1,199	5,616	7,330	5,953
Land	2,558	2,558	2,558	2,558
Buildings	4,970	4,970	4,970	4,930
Machinery	714.08	714.08	671.98	635.86

Source: S&P Global Market Intelligence. Standard template. Financial Sources.